ARTICLE | Clinical News

ETC-1002: Phase IIb data

October 6, 2014 7:00 AM UTC

Top-line data from the double-blind, U.S. Phase IIb ETC-1002-008 trial in 348 patients with hypercholesterolemia with or without statin intolerance showed that once-daily 120 or 180 mg oral ETC-1002 alone or in combination with 10 mg Zetia ezetimibe for 12 weeks all met the primary endpoint of reducing LDL-C from baseline to week 12 vs. Zetia. Specifically, mean reductions in LDL-C from baseline to week 12 were 27% for low-dose ETC-1002 (p=0.008); 30% for high-dose ETC-1002 (p<0.0001); 43% for low-dose ETC-1002 plus Zetia (p<0.0001); and 48% for high-dose ETC-1002 plus Zetia (p<0.0001) vs. 21% for Zetia alone. ...